DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20201753

A prospective study to compare the efficacy of vilazodone and escitalopram tablets in the treatment of patients with newly diagnosed major depressive disorder

Arjun Adiyodi, C. V. Singh, A. K. Mishra, Alok Dixit, Virendra Singh

Abstract


Background: With the availability of large number of anti-depressant drugs, a thorough knowledge of comparative efficacy of the commonly used antidepressants is necessary to prescribe best drug molecule to the patient. This improves the compliance and therapeutic outcome. The aim of the study is to compare the efficacy of vilazodone and escitalopram in the treatment of patients with newly diagnosed major depressive disorder in a prospective study.

Methods: 200 patients attending the psychiatry out-patient department diagnosed with major depressive disorder were assessed and enrolled into vilazodone 40 mg and escitalopram 20 mg treatment groups. Hamilton depression rating scale score (HDRS) was used to assess the severity of depression disorder at regular intervals.

Results: Maximum cases were in the 21-30 age group and minimum cases in above 60 years age group. Males contributed maximum to number of depression cases with respect to females in both the treatment groups. Both escitalopram and vilazodone therapy group showed onset of improvement   at the end of 1st week. The efficacy of both treatment arms in reducing HDRS is comparable till 2nd week of treatment, but at 6th month vilazodone was more efficacious than escitalopram therapy. 

Conclusions: Escitalopram tablet given once/twice daily is significantly effective in reducing HDRS score as early as 2nd week. At 6th month vilazodone tablet was more efficacious than escitalopram therapy. Vilazodone is safe with fewer adverse effects as compared to escitalopram.

 


Keywords


Anti-depressants, Vilazodone, Escitalopram, Major depressive disorder

Full Text:

PDF

References


World Health Organisation. Depression: Let’s talk. Brunier A: World Health Organisation; 2017 March 30. Available at: http://www.who.int/mental_health/ management/depression/en. Accessed on 6 March 2019.

World Health Organisation. Depression: overview. Tedros M: World Health Organisation; 25 March 2017. Available at: http://www.who.int/mediacentre/ factsheets/fs369/en. Accessed on 6 March 2019.

Akiskal HS. Mood disorders - historical introduction and conceptual overview. In: Sadock BJ, Sadock VA, Ruiz, Pedro (eds.) Kaplan and Sadocks Comprehensive Textbook of Psychiatry. Volume 1.10th Edition. Philadelphia, USA: Lippincott Williams and Wilkins; 2017:1559-1574.

Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-62.

Sadock BJ, Sadock VA, Ruiz P. (eds.) Kaplan and Sadocks Comprehensive Textbook of Psychiatry. Volume 1.10th Edition. Philadelphia, USA: Lippincott Williams and Wilkins; 2017:1594-1602.

Rossom RC, Solberg LI, Benitez GV, Whitebird RR, Crain AL, Beck A, et al. Predictors of poor response to depression treatment in primary care. Fam Pract. 2016;33:649-65.

Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L, Mahnert FA, Rouillon F et al. Prophylactic effect of citalopram in unipolar recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2001;178:304-10.

Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-9.

Katon W, Korff VM, Lin E, Simon G, Walker E, Bush T, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry. 1999;56:1109-15.

Hagop S, Akiskal. Mood disorders- Clinical Features. In: Sadock BJ, Sadock VA, Ruiz, Pedro. (eds.) Kaplan and Sadocks Comprehensive Textbook Of Psychiatry. Volume 1. 10th Edition. Philadelphia, USA: Lippincott Williams and Wilkins; 2017: 1611-1651.

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-17.

Shapiro D, Cook IA, Davydov DM, Ottaviani C, Leuchter AF, Abrams M. Yoga as a complementary treatment of depression: Effects of traits and moods on treatment outcome. Evid Based Complement Alternat Med. 2007;4:493-502.

Rush JA. Mood disorders- Treatment of depression. In: Sadock BJ, Sadock VA, Ruiz, Pedro. (eds.) Kaplan and Sadocks Comprehensive Textbook Of Psychiatry. Volume 1. 10th Edition. Philadelphia, USA: Lippincott Williams and Wilkins; 2017: 1652-1660.

Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Health Patient Saf. 2010;2:141-50.

Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740-3.

Belmaker RH. Bipolar disorder. N Engl J Med. 2004;351:476-86.

Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552-62.

Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am J Psychiatry. 2006;163:109-14.

Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Synopsis of Psychiatry.11th Edition. Philadelphia: Wolters Kluwer Publishers; 2015: 352-353.

Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psych Clin Practice. 2003;7(4):259-68.

Owens MJ, Rosenbaum JF. Escitalopram: a second-generation SSRI. CNS spectrums. 2002;7(1):34-9.

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Vilazodone for the treatment of depression: an update. Chonnam Medical J. 2016;52(2):91-100.